EP
ATRA icon

Elkfork Partners’s Atara Biotherapeutics ATRA Stock Holding History

Elkfork Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-277
Closed -$139K – 1054
2019
Q2 		$139K Sell
277
-87
-24% -$61.4K ﹤0.01% 892
2019
Q1 		$362K Sell
364
-366
-50% -$340K 0.01% 652
2018
Q4 		$634K Sell
730
-348
-32% -$323K 0.02% 457
2018
Q3 		$1.11M Buy
1,078
+73
+7% +$71.4K 0.03% 357
2018
Q2 		$923K Buy
1,005
+26
+3% +$27.9K 0.02% 362
2018
Q1 		$955K Buy
979
+827
+544% +$754K 0.03% 339
2017
Q4 		$69K Sell
152
-102
-40% -$37.7K ﹤0.01% 969
2017
Q3 		$105K Sell
254
-33
-11% -$12.4K ﹤0.01% 885
2017
Q2 		$100K Sell
287
-94
-25% -$36.2K ﹤0.01% 864
2017
Q1 		$196K Hold
381
– – 0.01% 593
2016
Q4 		$135K Buy
+381
New +$161K ﹤0.01% 664

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Elkfork Partners's ATRA Position: Q3 2019 in Review

Elkfork Partners sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 277 shares — an estimated $139K sold.

Elkfork Partners first reported a position in ATRA in Q4 2016 and held it in 11 quarters. The position peaked at $1.11M in Q3 2018. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

  • Elkfork Partners reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Elkfork Partners sold 277 Atara Biotherapeutics shares in Q3 2019, an estimated $139K.
  • Elkfork Partners first reported a position in Atara Biotherapeutics in Q4 2016 and held it in 11 quarters.
  • Elkfork Partners's Atara Biotherapeutics position peaked at $1.11M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.